Price
1,457.4
-0.97%52W Range
Market Cap
₹30,913.72 Cr
Traded: ₹47.30 Cr (0.15%) 0.0x
Free Float: ₹3,573.63 Cr (1.32% of FF traded)
Volume · 60D trend
3.24 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +24.0% | +22.0% | -- | +18.0% | Decelerating |
| ROE | -- | +9.0% | +13.0% | -- | -- | Accelerating |
| Return | -- | -- | -- | +79.0% | -- | -- |
| Profit | -- | +42.0% | +226.0% | -- | +51.0% | Stable |
Quarterly Results
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 554 | 602 | 556 | 537 | 496 | 580 | 440 | 396 | 280 | 439 | 384 |
| Expenses | 406 | 426 | 369 | 392 | 375 | 422 | 320 | 293 | 254 | 315 | 287 |
| Operating Profit | 148 | 177 | 188 | 146 | 121 | 158 | 120 | 102 | 26 | 125 | 96 |
| OPM % | 27.0% | 29.0% | 34.0% | 27.0% | 24.0% | 27.0% | 27.0% | 26.0% | 9.0% | 28.0% | 25.0% |
| Other Income | 4 | 16 | 0 | 15 | 10 | 10 | 9 | 10 | 8 | 3 | 11 |
| Interest | 8 | 8 | 10 | 9 | 12 | 11 | 23 | 21 | 21 | 21 | 23 |
| Depreciation | 46 | 45 | 44 | 40 | 38 | 37 | 34 | 36 | 31 | 31 | 31 |
| Profit Before Tax | 98 | 139 | 134 | 112 | 81 | 119 | 72 | 55 | -18 | 76 | 53 |
| Tax % | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 26.0% | 25.0% | 25.0% | -25.0% | 26.0% | 25.0% |
| Net Profit | 73 | 104 | 100 | 84 | 60 | 88 | 54 | 42 | -14 | 56 | 40 |
| Exceptional Items | -- | 0 | -8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 3.5 | 4.9 | 4.8 | 4.0 | 2.9 | 4.2 | 2.6 | -- | -- | -- | -- |
| Sales Growth (YoY) | 11.7% | 3.8% | 26.4% | 35.6% | 77.1% | 32.1% | 14.6% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -8.0% | 8.3% | 3.5% | 8.3% | -14.5% | 31.8% | 11.1% | 41.4% | -36.2% | 14.3% | -- |
| OP Growth (YoY) | 22.3% | 12.0% | 56.7% | 43.1% | 365.4% | 26.4% | 25.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | -16.4% | -5.9% | 28.8% | 20.7% | -23.4% | 31.7% | 17.6% | 292.3% | -79.2% | 30.2% | -- |
| Profit Growth (YoY) | 21.0% | 18.0% | 98.0% | 102.0% | 548.0% | 57.0% | 36.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | 19.0% | 16.0% | 83.4% | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS Growth (QoQ) | -29.9% | 3.6% | 18.8% | 37.9% | -31.6% | 63.7% | -- | -- | -- | -- | -- |
| OP Margin | 26.7% | 29.4% | 33.8% | 27.2% | 24.4% | 27.2% | 27.3% | 25.8% | 9.3% | 28.5% | 25.0% |
| Net Margin | 13.2% | 17.3% | 18.0% | 15.6% | 12.1% | 15.2% | 12.3% | 10.6% | -5.0% | 12.8% | 10.4% |
| Material Cost % | 26.1% | 26.9% | 23.0% | 26.1% | 28.4% | 28.9% | 27.5% | 26.3% | 26.1% | 28.2% | 27.9% |
| Employee Cost % | 32.5% | 31.0% | 31.1% | 30.3% | 32.4% | 26.1% | 30.2% | 34.1% | 46.6% | 29.7% | 31.8% |
| P/S | 13.75 | 13.68 | 10.86 | 10.23 | -- | -- | -- | -- | -- | -- | -- |
| P/E | 85.13 | 85.30 | 70.01 | 72.71 | -- | -- | -- | -- | -- | -- | -- |
| P/B | 12.45 | 12.07 | 10.38 | 9.25 | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Information relating to 27th Annual General Meeting (AGM) and Cut-off date for e-voting.
Newspaper Publication relating to 27th AGM (Pre-dispatch Advt.)
Transcript of Earnings Conference Call organised on 07 August 2026
Newspaper publication for Un-audited Financial Results of the Company for the quarter ended on 30 June 2026
Investor Presentation for the quarter ended on 30 June 2026
Recording of Earnings Call for the Unaudited Financial Results of the Company for the quarter ended on 30 June 2026.
Monitoring Agency Report for the Quarter ended on 30 June 2026
Unaudited Financial results (Standalone and Consolidate) for the Quarter ended on 30 June 2026
Press Release for the Unaudited financial results for the quarter ended 30 June 2026
Allotment of 18,700 equity shares under Employee Stock Option Plan
Board Meeting Outcome for Approval of Unaudited Financial Results (Standalone and Consolidated) For the Quarter Ended On 30 June 2026
Allotment of 8,900 Equity Shares under ESOP 2008 Scheme of the Company
Please refer to enclosed Intimation
Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Un-audited Financial Results ....
Trading Window Closure Intimation
Allotment of 1,70,501 Equity Shares under ESOP schemes of the Company.
Analyst/Investor Meet on 11 June 2026 at Hyderabad
Intimation of schedule of meeting with analyst / Investor on 3rd and 4th June 2026 at Mumbai.
Transcript of Earnings Call for the Audited Financial Results for the quarter and year ended 31 March 2026.
Newspaper publication for the Audited Financial Results for the quarter and year ended 31 March 2026.
Recording of Earnings Call for the Audited Financial Results for the quarter and year ended 31 March 2026.
Allotment of 92,000 Equity Shares under ESOP Schemes of the Company.
Monitoring Agency Report for the quarter and year ended 31 March 2026.
Investor Presentation for the quarter and year ended 31 March 2026.
Please refer to the attached intimation.
Press Release for the Financial Results for the quarter and year ended 31 March 2026.
Considered and Approved the Audited Financial Results for the Financial Year ended 31st March, 2026.
Please refer to the attached intimation.
Audited Financial Results for the year ended 31 March, 2026
Earnings conference call invite for the quarter and year ended Financial Results ended on 31 March, 2026
Intimation for Achievement of 100% renewal Power at Bidar Campus of the Company.
Please refer to the enclosed intimation.
Allotment of 2,44,281 Equity Shares under ESOP Schemes of the Company.
Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Audited Financial Results ....
Please refer to the enclosed Intimation.
Appointment of Dr. John Pavey, Head-Global PR&D as Senior Management Personnel of the Company w.e.f. 1 April, 2026 and retirement of Dr. Dean David Edney effective from the close of business ....
Trading Window Closure Intimation.
Allotment of 11,100 Equity Shares under ESOP 2008 Scheme of the Company.
Please refer enclosed intimation.
Schedule of meeting with analyst / Investor on March 13, 2026, at Hyderabad
Revised Intimation for allotment of 139007 shares under ESOP Schemes of the Company.
Credit Rating Letter issued by ICRA Limited.
Please refer enclosed intimation.
Please refer enclosed Intimation.
Earnings call transcript for the Un-audited Financial Result for the quarter and nine months ended on 31 December 2025.
Monitoring Agency Report for the quarter and nine months ended on 31 December, 2025.
Newspaper Publication for the Unaudited Financial Results for the quarter and nine months ended on 31 December 2025.
Investor Presentation for the third quarter and nine months ended on 31 December, 2025.
Recording of Earnings Call for the Unaudited Financial Results of the Company for the quarter and nine months ended on 31 December 2025.
Press Release for the Un-audited Financial Results for the quarter and nine months ended on 31 December 2025.
Annual Reports
12025
Credit Ratings
6Concalls
6Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Held by ETFs
19 ETFs hold sailife · sorted by weight
Held by Mutual Funds
108 schemes hold sailife · sorted by weight